Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis

De Rubis, G; Rajeev Krishnan, S; Bebawy, M

Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis

De Rubis, G

Rajeev Krishnan, S Bebawy, M

Permalink

Publication Type:: Journal Article
Citation:: Trends in Pharmacological Sciences, 2019, 40 (3), pp. 172 - 186
Issue Date:: 2019-03-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted manuscriptAdobe PDF (1.28 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	De Rubis, G https://orcid.org/0000-0001-7088-396X	en_US
dc.contributor.author	Rajeev Krishnan, S	en_US
dc.contributor.author	Bebawy, M https://orcid.org/0000-0003-2606-921X	en_US
dc.date.available	2020-05-25T19:02:47Z
dc.date.issued	2019-03-01	en_US
dc.identifier.citation	Trends in Pharmacological Sciences, 2019, 40 (3), pp. 172 - 186	en_US
dc.identifier.issn	0165-6147	en_US
dc.identifier.uri	http://hdl.handle.net/10453/136289
dc.description.abstract	© 2019 Elsevier Ltd Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material (the ‘tumor circulome’), represent an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies. Within the tumor circulome, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are the only components the clinical application of which is approved by the US Food and Drug Administration (FDA). Extracellular vesicles (EVs), circulating tumor RNA (ctRNA), and tumor-educated platelets (TEPs) are relatively new tumor circulome constituents with promising potential at each stage of cancer management. Here, we discuss the clinical applications of each element of the tumor circulome and the prevailing factors that currently limit their implementation in clinical practice. We also detail the most recent technological developments in the field, which demonstrate potential in improving the clinical value of liquid biopsies.	en_US
dc.relation.ispartof	Trends in Pharmacological Sciences	en_US
dc.relation.isbasedon	10.1016/j.tips.2019.01.006	en_US
dc.subject.classification	Pharmacology & Pharmacy	en_US
dc.subject.mesh	Animals	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Neoplasms	en_US
dc.subject.mesh	Prognosis	en_US
dc.subject.mesh	Liquid Biopsy	en_US
dc.title	Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	40	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
utslib.for	1112 Oncology and Carcinogenesis	en_US
utslib.for	06 Biological Sciences	en_US
utslib.for	11 Medical and Health Sciences	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	40	en_US

Abstract:

© 2019 Elsevier Ltd Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material (the ‘tumor circulome’), represent an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies. Within the tumor circulome, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are the only components the clinical application of which is approved by the US Food and Drug Administration (FDA). Extracellular vesicles (EVs), circulating tumor RNA (ctRNA), and tumor-educated platelets (TEPs) are relatively new tumor circulome constituents with promising potential at each stage of cancer management. Here, we discuss the clinical applications of each element of the tumor circulome and the prevailing factors that currently limit their implementation in clinical practice. We also detail the most recent technological developments in the field, which demonstrate potential in improving the clinical value of liquid biopsies.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/136289